7D1O

Crystal structure of SARS-Cov-2 main protease with narlaprevir

Summary for 7D1O

• Entry DOI: 10.2210/pdb7d1o/pdb
• Descriptor: 3C-like proteinase, (1R,2S,5S)-3-[N-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-L-valyl]-N-{(1S)-1-[(1R)-2-(cyclopropylamino)-1-hydroxy-2-oxoethyl]pentyl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide (3 entities in total)
• Functional Keywords: sars-cov-2, main protease, narlaprevir, viral protein
• Biological source: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
• Total number of polymer chains: 1
• Total formula weight: 34535.53

Authors

Fu, L.F.,Feng, Y.,Qi, J.X. (deposition date: 2020-09-15, release date: 2020-09-23, Last modification date: 2023-11-29)

• Primary citation: Bai, Y.,Ye, F.,Feng, Y.,Liao, H.,Song, H.,Qi, J.,Gao, G.F.,Tan, W.,Fu, L.,Shi, Y.; Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir.; Signal Transduct Target Ther, 6:51-51, 2021; PubMed: 33542181; DOI: 10.1038/s41392-021-00468-9

Experimental method

X-RAY DIFFRACTION (1.78 Å)